BioSpace News Archive

Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with hepatocellular carcinoma (HCC) has been dosed with MIV-818 in a phase 1b /2a combination study with the company’s candidate drug MIV-818.

AnHeart Therapeutics today announced the completion of a $61 million oversubscribed Series B financing round led by new investor Octagon Capital, with participation from Innovent Biologics, Cenova, Laurion Capital, and Sage Partners.

Cognito Therapeutics announced today the appointment of Jennifer Newberger as Vice President, Head of Regulatory Affairs and Compliance.

Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced clinical study results using the Cellworks Biosimulation Platform and Computational Omics Biology Model (CBM) to predict therapy response for individual Mantle Cell Lymphoma (MCL) patients were featured in a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Agreement includes an upfront payment of $100 million,

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released the updated data from three clinical studies of the company’s novel drug candidate, olverembatinib, at the 63rd American Society of Hematology (ASH) Annual Meeting.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer (CFO), effective immediately.

Today, Ubiquigent Limited (Ubiquigent) celebrates the 10th anniversary of its DUBprofiler™ compound profiling platform, together with KSQ Therapeutics joining its expanding customer base.

SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, today announced the tripling of its footprint on the West Coast with the opening of the world’s largest multi-modality and multi-product cGMP center for cell and gene therapies.

Provectus Algae (Provectus), an Australian synthetic biology company specializing in biomanufacturing to produce specialty ingredients for a wide array of industries and applications, has secured $11.4 million in a pre-series A funding round co-led by Hitachi Ventures, the corporate venture capital arm of Hitachi and Vectr Ventures of Hong Kong.